The Bone Core of the Program Project will provide shared facilities and services for processing and interpretation of tissues from the animal models utilized in all projects of the program. The overall goal of the core facility is to provide centralized histologic and image analysis support for investigators in the project. The following services will be provided: experimental design/consultation regarding endpoint analyses for histologic specimens, processing of osseous tissues for histologic analysis (decalcified and undecalcified sections, bone histomorphometric analysis of osseous sections (i.e., interpretation), and histologic analysis of soft tissue metastases or other soft tissue lesions with their pathologic diagnosis. In addition to histologic support, the core will provide services of FAXITRON microradiography and dual x-ray absorptometry (DEXA). The bone core will build on existing expertise in the School of Dentistry that includes the processing of soft tissue specimens and decalcified hard tissue specimens. These existing activities will be facilitated for investigators in the program through the staff of the bone core. In addition, new services of processing undecalcified osseous specimens will be initiated using plastic embedding techniques. The core facility will provide interpretation of the pathologic lesions (hard and soft tissue) through the expertise of a Board Certified Veterinary Pathologist, Dr. Thomas J. Rosol. Complete static and dynamic bone histomorphometric analysis will be performed by an experienced bone histomorphometrist (Yao) in conjunction with our consultant and highly regarded bone histomorphometrist, Dr. Robert Recker. Core support of these services will promote efficiency of specimen analysis and facilitate interactions between projects through the similar model systems and their common analyses. A significant benefit to the program as a group will be a standardized format for analysis of specimens from the common animal models that will be using different experimental approaches/targets (e.g., PAR1, SDF and CXCR4, BMPs and PTHrP). This will provide valuable information that can be shared and compared across the projects in the program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA093900-05
Application #
7614527
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-05-01
Budget End
2009-04-30
Support Year
5
Fiscal Year
2008
Total Cost
$204,458
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176

Showing the most recent 10 out of 228 publications